FIT checks for blood in the stool, which can indicate the presence of colorectal cancer or polyps. Patients collect stool ...
EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in ...
Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...
EL PASO, Texas (KFOX14/CBS4) — A doctoral student at the University of Texas at El Paso is digging deep with a new, less invasive way of undergoing a colonoscopy procedure. According to a statement ...
SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...
The recommendation addresses a long-standing treatment gap for patients facing bladder removal after standard therapy fails.
ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder ...
A study of data from seven outpatient facilities in the New York region found that 20–24% of all the breast cancers diagnosed ...